| abstract |
A nasally administrable composition which contains physiologically active compounds such as insulin, calcitonin, prostaglandin (PG) derivatives, monoclonal antibodies or interleukin derivatives (IL), and is enhanced in the in vivo absorbability of the physiologically active compound when administered nasally. The compositions are prepared by mixing fine particulate of the physiologically active compound with fine particulate of carrier having a mean particle size from 15 mum to 300 mum, and particle surface area from 0.1 to 0.4 m2/g, a which adhere to the mucous membrane of the nasal cavity, and HPC-H as absorption accelerator. |